"Neuroendocrine Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Descriptor ID |
D018358
|
| MeSH Number(s) |
C04.557.465.625.650 C04.557.580.625.650
|
| Concept/Terms |
Neuroendocrine Tumors- Neuroendocrine Tumors
- Neuroendocrine Tumor
- Tumor, Neuroendocrine
- Tumors, Neuroendocrine
|
Below are MeSH descriptors whose meaning is more general than "Neuroendocrine Tumors".
Below are MeSH descriptors whose meaning is more specific than "Neuroendocrine Tumors".
This graph shows the total number of publications written about "Neuroendocrine Tumors" by people in this website by year, and whether "Neuroendocrine Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 0 | 2 |
| 2013 | 3 | 0 | 3 |
| 2014 | 6 | 0 | 6 |
| 2015 | 5 | 1 | 6 |
| 2016 | 2 | 2 | 4 |
| 2017 | 4 | 0 | 4 |
| 2018 | 4 | 0 | 4 |
| 2019 | 7 | 0 | 7 |
| 2020 | 4 | 0 | 4 |
| 2021 | 3 | 0 | 3 |
| 2022 | 6 | 0 | 6 |
| 2023 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuroendocrine Tumors" by people in Profiles.
-
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2023 Nov 01; 30(11).
-
Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs. Cancer Imaging. 2023 Apr 25; 23(1):41.
-
Number of Hepatic Resections and Association with Complication after Metastatic Neuroendocrine Tumor Debulking: An American College of Surgeons NSQIP Database Study. J Am Coll Surg. 2023 07 01; 237(1):157-168.
-
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients. Eur Radiol. 2023 May; 33(5):3416-3424.
-
Novel treatment strategy of targeting epigenetic dysregulation in pancreatic neuroendocrine tumors. Surgery. 2023 04; 173(4):1045-1051.
-
Light It Up! The Use of DOTATATE in Diagnosis and Treatment of Neuroendocrine Neoplasms. Surg Pathol Clin. 2023 Mar; 16(1):151-161.
-
All Together Now: Standardization of Nomenclature for Neuroendocrine Neoplasms across Multiple Organs. Surg Pathol Clin. 2023 Mar; 16(1):131-150.
-
Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239.
-
First Differentiate and Then Operate (Or Not) : Editorial on "Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis". Ann Surg Oncol. 2022 06; 29(6):3371-3372.
-
Recurrent Loss of Heterozygosity in Pancreatic Neuroendocrine Tumors. Am J Surg Pathol. 2022 06 01; 46(6):823-831.